Search

Displaying results 351 - 360 of 4600 in total
  1. Drug

    Acemetacin

    go.drugbank.com/drugs/DB13783
    ApprovedInvestigational

    Merck and Company in Germany as an attempt to provide a safer drug but other than the amelioration on the gastrointestinal effects, the metabolism of acetamicin led to the formation of indomethacin and … it kept the same side effects.

  2. Drug

    Fenproporex

    go.drugbank.com/drugs/DB01550
    ApprovedIllicitWithdrawn

    In 2006 and 2009, the FDA issued warnings that it had been detected in diet pills sold online, and imported from foreign manufacturers. … It is listed as an illicit substance in many countries due to addiction issues and listed as a prohibited substance by the World Anti-Doping Agency.

  3. Drug

    Acarbose

    go.drugbank.com/drugs/DB00284
    ApprovedInvestigational

    [L31633,A37868] By inhibiting the activity of these enzymes, acarbose limits the absorption of dietary carbohydrates and the subsequent postprandial increase in blood glucose and insulin levels.

  4. Drug

    Levoleucovorin

    go.drugbank.com/drugs/DB11596
    ApprovedInvestigational

    However, in order to function in this role, it must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (THF). … Folic acid is an essential B vitamin required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein.

  5. Drug

    Belumosudil

    go.drugbank.com/drugs/DB16703
    ApprovedInvestigational

    [L34754] In July 2022, Belumosudil was approved by Health Canada under the brand name RHOLISTIQ to treat the same condition in adult and pediatric patients 12 years or older.[L42925] … [A236644,L34759] Belumosudil was first approved by the FDA in July 2021, under the brand name Rezurock, for the treatment of chronic GVHD in patients who have tried and failed at least two prior lines

  6. Drug

    Avanafil

    go.drugbank.com/drugs/DB06237
    Approved

    In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively

  7. Drug

    Nateglinide

    go.drugbank.com/drugs/DB00731
    Approved

    One minor metabolite, the isoprene, has the same potency as its parent compound. … The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents.

  8. Drug

    Prenylamine

    go.drugbank.com/drugs/DB04825
    ApprovedWithdrawn

    Prenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.

  9. Drug

    Avelumab

    go.drugbank.com/drugs/DB11945
    ApprovedInvestigational

    [A261496] On September 18 and December 18 of the same year, it was also granted approval by EMA [L48126] and Health Canada,[L48171] respectively. … [A261496] Avelumab was first approved by the FDA on March 23, 2017.

  10. Drug

    Mepivacaine

    go.drugbank.com/drugs/DB00961
    ApprovedInvestigationalVet approved

    A local anesthetic that is chemically related to bupivacaine but pharmacologically related to lidocaine. It is indicated for infiltration, nerve block, and epidural anesthesia. … Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168)